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Summary: A heterogeneous (solid-phase Separation) fluoroimmunoassay for digoxin in serum was developed
employing antibodies coupled to magnetisable cellulose/iron oxide particles and a fluorescein-labelled digoxin
derivative s tracer. Intrinsic fluorophores and other potentially interfering components of serum samples were
reliably and completely removed at the Separation and wash Steps of the assay procedure which were facilitated
by magnetic Sedimentation. In order to attain adequate sensitivity (detec'tion limit 0.2 μg/l (0.26 nmol/1) serum
digoxin), a sample volume of 500 μΐ was necessary. Assay results for patients' specimens correlated well with those
obtained using established charcoal-separation (r = 0.96) and magnetisable solid-phase (r = 0.95) radioimmuno-
assays. The feasibility of a "stat" adaptation of the fluoroimmunoassay that involved only two Standards (0.5 and
4 Mg/1 digoxin) was demonstrated. The stat method would be suitable for the assay of urgent or single specimens.
Fluoroimmunassay f r Digoxin im Serum
Zusammenfassung: Ein heterogener Fluoroimmunassay mit Festphasentrennung f r Digoxin im Serum wurde ent-
wickelt. Dabei wurden an magnetisierbare Cellulose/Eisenoxid-Partikel gekuppelte Antik rper und ein Fluorescein-
markiertes Digoxinderivat als Tracer verwendet. Im Serum enthaltene Fluorophore und andere m glicherweise
st rende Bestandteile wurden zuverl ssig und vollst ndig bei den Trenn- und Waschschritten des Bestimmungsver-
fahrens entfernt, erleichtert durch die magnetische Sedimentation. Um ad quate Empfindlichkeit (Nachweisgrenze
f r Digoxin 0,2 μg/l (0,26 iimol/1) Serum) zu erreichen, war ein Probenvolumen von 500 μΐ erforderlich.
Die Ergebnisse des Assay f r Patientenproben korrelierten gut mit denen von Radioimmun ssays mit der bew hrten
Trennung durch Charcoal (r = 0,96) oder magnetisierbare Festph sen (r s 0,95). Die Durchf hrbarkeit einer "Stat"-
Adaptation des Fluoroimmunassay mit nur zwei Standards von 0,5 und 4 /zg/1 Digoxin wird gezeigt. Die "Stat"-
Methode wird f r Notfall- oder Einzelproben als geeignet angesehen.
Intrqduction 125I-labelled materials have limited shelf-life. In addi-
Digoxin is the most widely used cardiac glycqside in the tion, there is significant legislative or emotive bias against
tre tment of congestive heart failure and cejrtaiii disturb^ the se of radioisotopes in some countries.
ances of cardiac rhythm (1). Dosage must be carefully „ ,* i ** n\ j u *
,. . , . « .
 J
 *· Λ ^ rr χ ι-·ι Homogeneous (6,7,10,11) and heterogeneous
adjusted to achieve Optimum therapeutic effects while ,ΛΛ * . ' ' / C T A \ r *· - u
•A· * · -4. τι_ ι r ι * · · ' ΓΛ- - (11—13) enzyme-immunoassays(EIA) for digoxin have
avoidmgtoxicity.The valueofmonitonngof digoxin ^ j , , , . ι / « - Λ Ο Ϊ Αi i - A '\· -j ι χ "jΓ iJi. u - x t been developed and shown to correlate well with RIAlevels in serum (2-4) is widely accepted, altho gh it has ,, _ ,
 Λ Λ ** ττ χ, . r
been pointed out that the usefolness of such meEure- <6' 1\ ll> «)· Ho««w, the measurement of enzyme
ments in the diagnosis of drug-related toxicity has not &<*ινι* «ff«of ^ '^ woassay may reqmre extra
beenconclusivelyproven(5).Radioimmunoassays(RIA) , reagent.add.t.on Steps ormanipulation to Start or stop
employing 3H-labelled digoxin (2,4,6) or a 125I-labelled 'ff™<l l~13 ' cnt;c^ tmunS °kr temPe.rature contro1
digoxin derivative (6-9) s tracer are most commonly g·7«12)'^d r^*lve y l?ng mcubation times
used. The latter have many advantages including thei? <between 30 and 60 mm for the ^ οχιη «"^)·
high sensitivity (low sample volume requirement) and Fluoroimmunoassay (FIA) techniques have the advantage
the convenience of gamma-radiation counting, but that fluorescence may be measured simply and rapidly.
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This report describes an F1A for serum digoxin that
employs antibodies coupled to magnetisable solid-
phase particles and a fluorescein-labelled digoxin
derivative äs tracer. The "sequential addition" pro-
cedure (14), in which the antibody reagent is first in-
cubated with the sample and then separately with the
tracer, was adopted.
Materials and Methods
Reagents
Digoxin, digoxigenin, l-ethyl-3-(3-dimethylanünopropyl)-carbo-
diimide hydrochloride, N-hydroxysuccinimide, and spirono-
lactone were obtained frorn Sigma, Poole, Dorset, U.K.; digoxi-
genin monodigitoxoside, digoxigenin bis-digitoxoside, and
dihydrodigoxin from Boehringer Mannheim, Mannheim,
F.R.G.; carboxymethoxylamine hemihydrochloride from
Aldrich, Gillingham, Dorset, U.K.; sodium metaperiodate from
BDH, Poole, Dorset, U.K.; canrenone and potassium canrenoate
from Searle, High Wycombe, Buckinghamshire, U.K.;bovine
albumin (fraction V) from Armour, Eastbourne, Sussex, U.K.;
silica-gel thin-layer chromatography sheets (DC Alufolien Kiesel-
gel 60 F2$4) from Merck, Darmstadt, F.R.G.;and magnetisable
cellulose/iron oxide particles from Technia Diagnostics, London
EC1,U.K. ·
Digoxin tracer
Either digoxin or digoxigenin bis-digitoxoside was used äs
starting material, with identical procedures thioughout.
Coupling of di-(O-carboxymethyl)oxime derivative to fluores-
ceinthiocarbamyl ethylenediamine
l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(9.5 mg) and N-hydroxysuccinimide (0.5 mg) were dissolved in
l ml of dimethylformamide. pi-(O-carboxymethyl)oxime sölution
(400 ) was ädded and the reaction mixture stirred for l h. To
the resulting active ester solütiori was added dropwise 500 of
a 4 g/l sölution of fluoresceinthiocarbafhyl ethylenediamine in
dimethylformamide. After stirring for a furtherf20 min, the
reaction mixture was applied to silica-gel sheets (250 per
sheet) which were developed with chloroform/methanol/
ammonia (40 + 30 + 5 by volume) to separate three yellöw-
örange products (designated A, B, and C) with Rf values 0.76,
0.50, and 0.40, respectively. (Fluoresceinthiocarbarnyl ethylene-
diamine had Rf 0.05 in this System.) The area of each product
was scraped from the sheets, the scrapings eluted with l ml of
methanol per sheet, and the eluates stored in the dark at 4 °C.
The concentration of each product was estimated by dilution in
sodium bicarbonate buffer (50 mmol/1, pH 9;0) and measure-
ment of absorbance at 492 nm due to the fluorescein group.
A molar lineic absorbance of 87.8 m* - 1
(8,78 X 1Ö4 l - mol"1 · cm"1) was assumed (15).
Anti-digoxin magnetisable solid-phase
Sheejp anti-digoxin serum, raised against an irhmünogen pre-
pared by linking 3-O-suceinyl digoxigenin to bovine albumin
by the mixed-anhydride procedüre (16), was obtained from
Technia Diagnostics. Following established methods (15), whole
antiserüm (50 ) mixed with normal sheep senini (950 )
was coupled to magnetisable particles (l g) that had been
activated with cyanogen broniide. Äe product was suspended
to 50 g/l in düuent buffer and stored at 4 °C.
Dialdehyde derivative
Digoxin or digoxigenin bis-digitoxoside (50 mg) was dissolved
in a mixture of 3 ml of methanol and l ml of Chloroform. To the
stirred sölution was added dropwise 500 of 10 g/l aqueous
sodium metaperiodate. Stirring was continued for 45 min, then
the reaction mixture was evaporated to dryness under a stream
of nitrogen. Chloroform (3 ml) was added to the residue and
shaken thoroughly. The Chloroform extract was separated from
the inorganic solids, 100 mg of anhydrous magnesium sulphate
added, and the mixture stood for l h. The Chloroform layer was
again separated from the solids and evaporated to dryness under
nitrogen. The product was dissolved in ethanol to 25 g/l. Thin-
layer chromatography with the solvent System Chloroform/
methanol (9 +1 by volume) showed one cpmponent at Rf
0.50 (detected by spraying with methanol/concentrated
sulphuric acid (9 + 1 by volume) and warming briefly to develop
a grey-brown colour).
Di-(O-carboxymethyl)oxime derivative
Sodium acetate (30 mg) and carboxymethoxylamine hemihydro-
chloride (35 mg) were dissolved in 150 of water in a 5 ml
round-bottomed flask. Dialdehyde sölution (l ml) was ädded
and the reaction mixture refluxed on a boiling water bath for
l h. The course of reaction was followed by thin-layer chromato-
graphy using chloroform/acetone/glacial acetic acid (7 + 2 + 1
by volume). A single major product appeared at Rf 0.16
(detected with methanol/sulphuric acid äs described above).
The reaction mixture was reduced to a small volume under a
stream of nitrogen, diluted with l ml of water, then extracted
twice with 2 ml of ethyl acetate. The organic extracts were
combined and dried over anhydrous magnesium sulphate. The
ethyl acetate layer was separated from the solids and evaporated
to dryness under nitrogen. The product was dissolved in dimethyl-
formamide to 10 g/l.
Fluoresceinthiocarbamyl ethylenediamine
Prepared äs described previously (15).
Fluoroimmunoassay Standards
A sölution pf digoxin in ethanol (250 mg/1) was diluted in
pooled normal human serum. Standards were stored at — 20' 'C.
Patients' specimens
Serum specimens were taken at random from those submitted
for digoxin assay to the Routine Laboratory, Department of
Chemical Pathology, St. Bartholomew's Hpsjpital, London EC1,
U.K. (Plasma specimens were not suitable for assay by FIA
because of a tendency to aggregate the solid-phase particles).
Radioimmunoassay procedures
Digoxin levels in patients' specimens were determined in the
Hospital laboratory by a charcoal-separatioii RIA employing
125I-läbelled digoxin. The specimens were also assayed using
magnetisable solid^phase RIA kits with 125I-tracer (Technia Dia-
gnostics), which were used according to the manufacturer's
instructions.
Fluoroimmunoassay procedures
Düuent buffer
Sodium borate buffer (200 mmol/1, pH 9.5) containing l g/l
bovine albumin and l g/l sodium azide.
Wash buffer
Sodium borate buffer (20 mmol/1, pH 9.5) containing l gA
bovine albumin and l g/l sodium azide.
Test tubes
Pisposäble polystyrene test tubes (55 X 12 mm, No. 55.484)
from Walter Sarstedt, Leicester, Leies., U.K. *
Magnet
Multi-polar ferrite block magnet with flat surface approx.
150 X 200 mm from Magnet Appücatipns, London EC1, U.K.
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Fluorimeter
Perkin-Elmer Model 1000 fluorimeter (Perkin-Elmer, Beacons-
field, Bucks., U.K.) equipped with Alters and modified fox
fluorimetry with disposable test tubes s described previously
(14).
Assay protocol
All operations were performed at room temperature, in duplicate.
Serum samples (500 μΐ) were dispensed into test tubes. To each
tube was added 100 μΐ of anti-digoxin solid-phase Suspension
(12 g/l in diluent buffer). Tlie tubes were vortexed and incubated
for 20 min with a vortex after 10 min to prevent excessive gravi-
tationaJ settling of the solid-phase particles. The rack containing
the tubes was placed on the magnet and the solid phase allowed
to sediment magnetically over about 5 min, then the supernatants
were aspirated to waste. Wash buffer (1.5 ml) was added, the
tubes vortexed, and the solid phase again sedimented on the
magnet and the supernatants aspirated to waste. To each tube was
added 100 μΐ of digoxin tracer (33 nmol/l in diluent buffer). The
tubes were vortexed and incubated for 20 min with a vortex
after 10 min. Wash buffer (1.5 ml) was added, the tubes vor-
texed, and the solid phase sedimented on the magnet. The
fluorescence of the supernatants was measured by placing each
test tube directly in the fluorimeter.
Results
Characterisation of digoxin tracer
Fluorescent tracer products A, B, and C were assessed
by measurement of immunoreactivity using excess anti-
digoxin solid phase. Values of 55,70, and 40%,
respectively, were obtained for tracers prepared from
either digoxin or digoxigenin bis-digitoxoside. Typical
concentrations of product Solutions in methanol were
15,60, and 45 μτηοΐ/ΐ, respectively. Product B was
accordingly chosen for use in the FLA. No attempt was
made to characterise further the various tracer pro-
ducts.
The results described below were obtained with a
tracer prepared from digoxigenin bis-digitoxoside. How-
ever, tracer prepared by labelling digoxin behaved iden-
tically in the FIA.
Assay r nge and detectability of digoxin
The FIA covered the clinically important therapeutic
and toxic concentration ranges (2—4) for digoxin
(flg. 1). The minimal detectable concentration (17) of
digoxin in serum at the 95% confidence level was 0.2
/ig/l (0.26 nmol/l). The minimal detectable dose (17)
was 0.1 ng (0.13 pmol) of digoxin per tube.
Precision
Within-assay precision was assessed by measuring each
of three serum specimens 10 times in duplicate, giving
mean results l .1,2.2, and 3.1 μg/^, with coefficient of
Variation (CV) of 9.6,4.5, and 4.2%, respectively. Assay
of the same specimens in duplicate on each of 10 dif-
ferent days gave between-assay CV results of 12.6,6.6,
and 4.2%, respectively.
Recovery
Digoxin was added at different levels to each of two
specimens of normal human serum. Analytical recovery
of l μg/l added digoxin was 90.5 and 107.5% and that
of 2.5 Mg/1 added digoxin was 92 and 102%.
Specificity
Cross-reactivities of various substances in the digoxin
FIA were determined by the method of Abraham (18)
in which the amount of digoxin required to cause 50%
displacement of tracer from antibody is expressed s
a percentage of the amount of cross-reactant required
to produce the same effect. The digoxin metabolites
digoxigenin bis-digitoxoside, digoxigenin mono-digi-
toxoside, digoxigenin, and dihydrodigoxin cross-
feacted to 100,100,90, and 12%, respectively, and
the related drugs lanatoside C, digitoxin, gitoxin, and
ouabain to 96,3.4, 2.0, and 0.03%, respectively. No
detectable interference at a serum level of l g/l was
found with spironolactone, but its metabolites
canrenone and canrenoate cross-reacted to l .2 and
0.06%, respecfively. No detectable cross-reaction at
the l g/l level was found with amiodarone, cholesterol,
cortisol, disopyramide, oestriol, lidocaine, procain-
amide, progesterone, propranolol, quinidine, or
testosterone.
Correlation with radioimmunoassay methods
Results for the assay of 47 patients' specimens by the
FIA (y) and by the charcoal-separation RIA (x) were
related by the regression line y = 0.98 χ (calculated
assuming the two methods to have equal precision
0.80
0.70
-0.60
o
0.50
0.40 - l l ^
0.5 1 2
Digoxin concentration
Fig. 1. Standard curve for magnetisable solid-phasc fluoro-
immunoassay of digoxin in serum (logarithmic concen-
tration scale).
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characteristics (19)), with a correlation coefficient (r)
of 0.96 (flg. 2). Assay of 49 specimens by the FIA (y)
and by the magnetisable solid-phase RIA (x) yielded
a line y = 0.98 - 0.1, with r = 0.95 (flg. 3). For
comparison, the correlation between the established
magnetisable solid-phase (y) and charcoal-separation
(x) RIA methods was given by y = 0.99 + 0.1, with
r = 0.94 (46 specimens).
l l _L
0 1 2 3 4 5
Oigoxin (charcool-separotion radioimmunoassay)^g/(]
Fig. 2. Correlation between digoxin levels in patients' serum
specimens determined by magnetisable solid-phase
fluoroimmunoassay and by charcoal-separation radio-
immunoassay, showing the regression line calculated
assuming the two methods to have equal precision
characteristics (19).
"Stat" assay procedure
When plotted with a linear concentration scale, the
FIA Standard curve showed extensive linearisation
(fig. 4) which was consistently reproducible between
digoxin levels of 0.5 and 4 g/l. A stat assay procedure
was devised in which only two Standards with these
concentrations were emplqyed and the Standard curve
was constructed by drawing a straight line between
the corresponding points. Results for the assay of
48 patients' specimens calculated by the stat FIA
method (y) and by the normal FIA procedure with füll
Standard curve (x) were related by the regressipn line
y = 1.03 x, with r = 0.998.
Stabil-ity of fluoroimmunoassay reagents
Digoxin tracer preparations stored in methanol showed
no change in properties over at least one and a half
years, and anti-digoxin solid phase and digoxin serum
Standards were stable for at least two years.
CJ>
E 3
_L
0 1 2 3 4 5
Oigoxin (solid-phqse rgdioimmunoassay) i/tg/l]
Fig. 3. Correlation between digöxiri levels in patients' serum
specimens determined by magnetisable sölid-phäse
fluoroimmunoassay and by magnetisable solid-phase
radioimmunoassayj showing the regression line calculated
assuming the two methods to have eqüal precision
characteristics (19).
0.70
i 0,60
0.50
|- \
1 2 3
Oigoxin eoncentrdtiion
Fig. 4. Standard curve for magnetisable solid-phase fluoro-
immunoassay of digoxin in serum (linear concentration
scale).
Discussion
A clinically useful digoxin assay should cover the com-
monly encpuntered therapeutic and toxic concentra-
tions whieh Ue (2-^4) in the ränge 0.5 to S /^1 (0,6 to
6 nmpl/1). Such drug levels are easily determined by
RIA employing lisl-träcer (6—9). However, it is
apparent that this coneentration ränge represeiits the
practical Ümit of homogenepus
 § since for digoxin
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assay a sample volume of 200 and an incubation
period of 30 min are required (6,7,10) to achieve a
detection limit of 0.64 nmol/1 (l 1), and sample pre-
treatment with strong alkali (6,11) is necessary to
prevent interference by endogenous serum constituents
such äs certain dehydrogenases (l 1). In heterogeneous
EIA (11—13), sample interferences are removed in a
Separation step; one such assay, which has a detection
limit of 0.4 nmol/1 digoxin (11,12), requires 100
of sample and a 60 min incubation period for quanti-
tation of antibody-bound enzyme-labelled digoxin (12).
As compared with the determination of enzyme
activity, the measurement of fluorescence is rapid and
simple; in FIA studies in this laboratory, fluorescence
readings are routinely taken in five seconds using the
signal-averaging facility of the Perkin-Elmer Instrument.
As previously demonstrated (14), fluorescence of super-
natants above sedimented solid phase may conveniently
be determined directly in disposable polystyrene assay
tubes. In the digoxin FIA, the use of a heterogeneous
assay technique enables the reliable and complete re-
moval of serum fluorophores and other potentially
interfering components at the aspiration stages, while
the Separation Steps are facilitated by magnetic Sedi-
mentation. A general property öf the sequential addi-
tion procedure adopted in this work is that tracer and
sample are never in contact, and therefore non-specific
serum binding interferences are entirely obviated.
It was found that a sample volume of 500 was
necessary to attain acceptable sensitivity in the FIA
(detection limit 0.26 nmol/1 serum digoxin). Urider
the fluorimetric conditions used, the background
Signal (consisting of fluorescent and scättered light from
the wash buffer and the test tubes) amounted to about
10% of the total tracer Signal, and it was judged that
further significant improvement of assay sensitivity by
dilution of the tracer reagent (and the solid-phase antl·
body) was not feasible. Curry et al. (20) have described
a solid-phase FIA fof triiodothyronine that employs the
fluoresceinrlabelled hörmone äs tracer, requires a sample
volume of 100 , and has a detection limit of 03 nmol/1.
Together with the present results, this suggests that FIA
employiiig antigen labelled with a single fluorophore
and with quantitatiorj of this tracer by cpnventjonal
fluorimetry may be generally suitable for assay of serum
analy tes down to concentrations of a few nanomoles per
litre. Further sensitivity improvement in FIA might
require, for example, the applicätion of multi-flüoro-
phore-labelliiig techniques (21-24).
The term "stat" is usually applied to simplifled or
speeded test procedures that are suitable for assay of
urgent or single specimens. Stat adaptations of digoxin
RIA methods (8,9) have included reduction in the
number of calibrators so that the Standard curve is
plotted with three points orily. Einergency modifica-
tions of hömogeneous (6) and heterogeneous (12)
digoxin EIA involving only two serum Standards have
been proposed. A stat FIA requiring only two
Standards and relying on linearisation of the Standard
curve (fig. 4) was tested. Good correlation of assay
results with those obtained using a füll Standard curve
indicated the basic feasibility of this approach, but it
was not an aim of these studies to perform füll valida-
tion (precision, etc.) of the stat assay. In clinical appli-
cätion of any such method, the inclusion of quality-
control specimens in each assay run would be necessary,
in accord with normal practice, äs a confirmation of
accuracy (8).
The digoxin FIA employs stable, non-radioactive reagents
and may be performed using a simple filter fluorimeter.
Using the stat procedure, a result for an urgent specimen
could be obtained within about l h. The assay requires
a relatively large sample volume which could be a dis-
advantage in some circumstances. However, it was found
that the majority of specimens submitted to the Hospital
laboratory häd a volume greater than l ml and were
therefore suitable for duplicate determination by FIA.
Although the FIA correlated acceptably with two
established RIA methods, the cross-reactivity of can-
renone and canrenpate would suggest that in its present
form it is unsuitable for assay of specimens from patients
receiving spironolactone äs well äs digoxin. A similar
pröblem in heterogeneous EIA was overcome by a
change to a more specific antiserum reagent (12) and
this would presumably also be effective in the FIA
systerri.
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